SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Jun 8, 2025--
SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608851515/en/
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
About SOLVE FSHD
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
About Modalis Therapeutics Corporation
Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608851515/en/
CONTACT: SOLVE FSHD
Alexandra Grant, House of Wilson
[email protected]
Modalis Therapeutics Corporation
Corporate Planning Department
[email protected]
KEYWORD: MASSACHUSETTS NORTH AMERICA UNITED STATES ASIA PACIFIC JAPAN CANADA
INDUSTRY KEYWORD: RESEARCH GENETICS HEALTH TECHNOLOGY PHILANTHROPY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH OTHER PHILANTHROPY SCIENCE
SOURCE: SOLVE FSHD
Copyright Business Wire 2025.
PUB: 06/08/2025 07:30 PM/DISC: 06/08/2025 07:31 PM
http://www.businesswire.com/news/home/20250608851515/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
44 minutes ago
- Bloomberg
American Cars Could Use Toyota's Sales Network in Japan, VP Says
American carmakers looking to expand sales in Japan could consider using Toyota Motor Corp. 's domestic sales network, according to a senior executive of the Japanese carmaker. While US carmakers have 163 sales locations in Japan, Toyota holds more than 4,000, Chief Technology Officer Hiroki Nakajima said in a interview published Monday on the company's media site.
Yahoo
an hour ago
- Yahoo
Fraser Institute News Release: AI can help mitigate shrinking labour force by increasing productivity of existing workers and adding new ones
VANCOUVER, BC, June 10, 2025 /CNW/ - As Canada's labour force shrinks due to aging and slowing rates of immigration, artificial intelligence (AI) can help by increasing the number of available workers and improving worker productivity, finds a new study published today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank. "While there's a common perception that AI will eventually lead to mass unemployment, it actually opens the door to the labour market for people who may have been on the outside looking in," said Morley Gunderson, professor emeritus of economics at the University of Toronto and author of Can AI Mitigate Our Labour Force Problems? For example, AI can facilitate more effective job-matching between employers and job seekers including retirees who want to return to work, students who want part-time jobs, and new immigrants. AI can also improve employment prospects for people with disabilities by equipping employees with assistive technologies (screen readers, speech recognition software, etc.) and helping make driverless vehicles, "smart" wheelchairs and other AI-powered resources more widely available. At the same time, AI can help increase productivity growth, which has stagnated in Canada. For example, AI can help connect small and dispersed geographical markets with larger commercial centres, facilitate trade (within Canada and internationally), help small firms grow, and increase the ability of scientists and engineers to develop innovations that fuel productivity growth. "Rather than unduly fearing AI, Canadians should welcome the promise of AI to increase our ability to produce goods and services and improve our living standards," said Steven Globerman, senior fellow at the Fraser Institute. Follow the Fraser Institute on Twitter | Like us on Facebook The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, Montreal, and Halifax and ties to a global network of think-tanks in 87 countries. Its mission is to improve the quality of life for Canadians, their families and future generations by studying, measuring and broadly communicating the effects of government policies, entrepreneurship and choice on their well-being. To protect the Institute's independence, it does not accept grants from governments or contracts for research. Visit SOURCE The Fraser Institute View original content to download multimedia:
Bloomberg
an hour ago
- Bloomberg
China Sends Two Aircraft Carriers Into Pacific Ocean in a First
Japan said it observed two Chinese aircraft carriers and supporting warships operating simultaneously near remote Japanese islands in the Pacific Ocean for the first time, a new demonstration of Beijing's advancing naval capabilities. The aircraft carrier Shandong was seen sailing into the Pacific at the weekend and identified on Monday conducting fighter jet and helicopter take-off and landing training, according to Japan's Joint Staff Office. That was occurring inside the exclusive economic zone around the Japanese atoll of Okinotori, around 1,740 km south of Tokyo, the office said.
